Reported Monday, iPSC-Derived NK Cells Clinical Trial Pipeline Gains Momentum With 12+ Active Companies Developing Off-The-Shelf Cancer Immunotherapy Treatments Across Multiple Indications
Century Therapeutics, Inc. +4.41%
Century Therapeutics, Inc. IPSC | 2.37 | +4.41% |
Reported Monday, iPSC-Derived NK Cells Clinical Trial Pipeline Gains Momentum With 12+ Active Companies Developing Off-The-Shelf Cancer Immunotherapy Treatments Across Multiple Indications
